KRYS analyst estimates
Krystal Biotech (KRYS) analyst ratings, the average price target and its range, and every firm's latest call.
KRYS analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 24, 2026 | Goldman Sachs | Krystal Biotech resumed with a Buy at Goldman Sachs | $441.00 |
| Aug 14, 2026 | RBC Capital | Krystal Biotech initiated with an Outperform at RBC Capital | $400.00 |
| Jul 13, 2026 | Jefferies | Krystal Biotech price target raised to $474 from $399 at Jefferies | $474.00 |
| Jun 16, 2026 | H.C. Wainwright | Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright | $361.00 |
| May 5, 2026 | Evercore ISI | Krystal Biotech price target raised to $300 from $295 at Evercore ISI | $300.00 |
| Feb 18, 2026 | Chardan Capital | Krystal Biotech price target raised to $323 from $220 at Chardan | $323.00 |
| Feb 17, 2026 | Jefferies | Krystal Biotech price target raised to $371 from $310 at Jefferies | $371.00 |
| Jan 30, 2026 | Goldman Sachs | Krystal Biotech price target raised to $327 from $206 at Goldman Sachs | $327.00 |
| Jan 9, 2026 | H.C. Wainwright | Krystal Biotech price target raised to $310 from $240 at H.C. Wainwright | $310.00 |
| Oct 17, 2025 | Guggenheim | Krystal Biotech price target raised to $224 from $189 at Guggenheim | $224.00 |
| Aug 22, 2025 | Chardan Capital | Krystal Biotech price target lowered to $216 from $219 at Chardan | $216.00 |
| Sep 11, 2024 | Stifel Nicolaus | Krystal Biotech price target raised to $220 from $204 at Stifel | $220.00 |
| Sep 2, 2024 | Bank of America Securities | Krystal Biotech price target raised to $205 from $195 at BofA | $205.00 |
| Aug 12, 2024 | Evercore ISI | Krystal Biotech price target raised to $206 from $201 at Evercore ISI | $206.00 |
| Apr 15, 2024 | Stifel Nicolaus | Krystal Biotech (KRYS) PT Raised to $204 at Stifel | $204.00 |
- 11 firms rate KRYS: 10 buy, 1 hold, 0 sell.
- The average price target is $395.20 from 5 analysts, from $300.00 to $474.00.
Updated 2026-11-02 18:27 UTC